with invasive cancer and/or HIV;
- Published new immunological data in Gynecologic Oncology from a
Phase 2 clinical trial testing previous version of HspE7; 95 percent
of cervical dysplasia patients had regression or stable disease in
"We achieved many important milestones during this quarter," said Gregory M. McKee, President and Chief Executive Officer at Nventa. "With additional finances, depth and experience of the Board and Management team, and an impressive Clinical and Scientific Advisory Board, we are advancing HspE7, our lead therapeutic vaccine candidate, through clinical trials and are exploring ways to expand and progress our preclinical pipeline as well."
About Nventa Biopharmaceuticals Corporation:
Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The Company is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa Biopharmaceuticals Corporation, please visit the Company's website located at http://www.nventacorp.com.
The Audit Committee of the Company has reviewed and approved of the contents of this Press Release. Summary financials are attached below. The full financial statements and MD&A for the three and nine months ended September 30, 2007 can be found on SEDAR at http://www.sedar.com.
(financial information attached)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(Canadian dollars) (In thousands, except per share amounts)
Three months ended Nine months ended
|SOURCE Nventa Biopharmaceuticals Corporation|
Copyright©2007 PR Newswire.
All rights reserved